📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
51 announcements match the current filters (relevance ≥ 5).
Allcargo Global acquires remaining 10% stake in ECUnordicon AB for SEK 17.6 million
Allcargo Global's wholly-owned subsidiary, Ecu Global N.V., has acquired the remaining 10% stake in Swedish entity ECUnordicon AB for a cash consideration of SEK 17,600,000. This transaction, completed on July 29, 2026, increases Allcargo's total ownership in the target from 90% to 100%. The acquisition follows a put option exercise from a 2021 shareholder agreement. The target entity, operating in multimodal transportation, reported a 2025 turnover of SEK 462.5 million, reflecting a decline from SEK 541.8 million in 2024.
Confidence: HIGH
What changedAllcargo Global has moved from majority control (90%) to full ownership (100%) of its Swedish subsidiary, ECUnordicon AB.
Why it mattersFull ownership simplifies the corporate structure and allows Allcargo to fully consolidate profits and exercise complete strategic control over its Nordic multimodal transportation and warehousing business.
Acquisition Cost: SEK 17,600,000Stake Acquired: 10%Total Stake Post-Acquisition: 100%Target Turnover (2025): SEK 462,555,733Target Turnover (2024): SEK 541,851,764
📅 Short termNeutral to slightly positive as the company fulfills a long-standing contractual obligation to acquire the remaining stake, with minimal immediate impact on cash flows.
📈 Long termPositive structural move that consolidates the international logistics footprint, though the target's recent revenue volatility requires monitoring.
⚠ Risk flags
- Target turnover declined by approximately 14.6% between 2024 and 2025
Key Highlights
Acquisition of 76,924 shares (10% stake) to achieve 100% ownership of ECUnordicon AB
Cash consideration of SEK 17,600,000 paid for the final tranche
Target entity reported a turnover of SEK 462,555,733 for the Jan-Dec 2025 period
Transaction executed pursuant to a shareholder agreement dated July 29, 2021
Target turnover showed volatility, rising from SEK 392.6m in 2023 to SEK 541.8m in 2024 before dropping in 2025
👀 What to Watch
Investors should monitor the performance of the Nordic operations to see if 100% ownership leads to improved operational synergies and if the company can arrest the recent turnover decline in that region.
NCLT Sanctions Demerger of Bio Pharma and Spirits & Biofuel Units
India Glycols Limited (IGL) has received formal sanction from the NCLT Allahabad Bench for its Scheme of Arrangement. The scheme involves demerging the 'Bio Pharma' undertaking into Ennature Bio Pharma Limited and the 'Spirits and Biofuel' undertaking into IGL Spirits Limited. The proposal received 100% approval from voting equity shareholders and unsecured creditors representing Rs 642.66 Cr in value. The appointed date for this structural reorganization is April 1, 2026.
Confidence: HIGH
What changedThe company has cleared the final legal hurdle (NCLT sanction) to split its business into three distinct entities: Chemicals (Remaining IGL), Bio Pharma, and Spirits & Biofuel.
Why it mattersThis is a major structural reorganization aimed at unlocking value. By separating the high-growth Spirits and specialized Bio Pharma segments from the core industrial chemical business, the company can pursue independent capital allocation and potentially achieve better market valuations for each segment.
Appointed Date: 1st April, 2026Creditor Value in Favor: Rs 64,266.50 lakhShareholder Approval: 100%TTM Revenue: Rs 8,443 CrMarket Cap: Rs 7,258 Cr
📅 Short termThe stock may see positive sentiment as the regulatory uncertainty regarding the demerger timeline is now resolved.
📈 Long termStructural re-rating is possible as the Spirits business, which often commands higher P/E multiples than industrial chemicals, becomes a standalone entity.
⚠ Risk flags
- Operational transition risks during the separation of undertakings
- Regulatory compliance across multiple new entities
Key Highlights
Appointed date for the demerger is fixed as April 1, 2026
Unsecured creditors representing Rs 64,266.50 lakh in value voted 100% in favor of the scheme
Total of 4,42,48,626 equity shares voted unanimously in favor of the restructuring
Two new resulting companies created: Ennature Bio Pharma Limited and IGL Spirits Limited
NCLT order pronounced on July 17, 2026, following the second motion petition
👀 What to Watch
Watch for the announcement of the 'Effective Date' and the specific share entitlement ratio for the new entities once the certified order is filed with the Registrar of Companies.
NCLT Sanctions Demerger of Bio Pharma and Spirits & Biofuel Units
The National Company Law Tribunal (NCLT), Allahabad Bench, has sanctioned India Glycols' Scheme of Arrangement for the demerger of two major business segments. The Bio Pharma undertaking will be transferred to Ennature Bio Pharma Limited, and the Spirits and Biofuel undertaking will be transferred to IGL Spirits Limited. This move aims to streamline operations across the company's Rs 8,443 Cr TTM revenue base. The formal order was pronounced on July 17, 2026, marking a critical legal milestone for the restructuring.
Confidence: HIGH
What changedThe company has received formal legal approval from the NCLT to split its business into three distinct entities (the parent and two new resulting companies).
Why it mattersThis restructuring allows for independent management and capital allocation for the high-growth Bio Pharma and Spirits/Biofuel segments, which are currently part of a larger conglomerate structure with 7.3% OPM.
TTM Revenue: Rs 8443 CrDistillery Capex: Rs 365 CrMarket Cap: Rs 7361 CrOrder Pronouncement Date: 17th July 2026
📅 Short termThe stock may see positive momentum as the legal uncertainty regarding the demerger timeline is resolved.
📈 Long termStructural shift to specialized entities could lead to better valuation multiples for the Bio Pharma and Spirits businesses compared to the current consolidated P/E of 25.2.
⚠ Risk flags
- Execution risk during the transition of operations to new entities
- Regulatory transfer of liquor licenses to the new Spirits entity
Key Highlights
NCLT Allahabad Bench sanctioned the demerger scheme on July 17, 2026
Bio Pharma undertaking to be demerged into Ennature Bio Pharma Limited
Spirits and Biofuel undertaking to be demerged into IGL Spirits Limited
Restructuring involves a company with TTM revenue of Rs 8,443 Cr and a market cap of Rs 7,361 Cr
Company is currently undergoing a Rs 365 Cr capex for distillery capacity enhancement
👀 What to Watch
Investors should monitor the upcoming announcement of the 'Record Date' for the allotment of shares in the two new resulting companies. Track the listing timelines for Ennature Bio Pharma and IGL Spirits to assess the value unlocking potential.
AGL reports ₹290 cr Net Loss in FY26; Revenue down 9% amid geopolitical headwinds
Allcargo Global Limited (AGL) reported a challenging FY26, swinging to a consolidated Net Loss of ₹290 cr from a profit of ₹43 cr in FY25. Revenue declined 9% YoY to ₹12,758 cr as geopolitical tensions in West Asia and US trade tariffs impacted global trade volumes across LCL, FCL, and Air segments. Profitability was significantly weighed down by ₹236 cr in one-off items, including ₹32 cr for staff restructuring and ₹73 cr in one-off provisions. Despite the headline loss, the company achieved a 200 bps expansion in gross margins to 22% and reduced standalone debt to ₹314 cr.
Confidence: HIGH
What changedThe company swung from a profit to a significant loss in FY26, driven by a combination of lower global trade volumes and high one-off restructuring and write-off costs.
Why it mattersThe results highlight the high sensitivity of AGL's global logistics business to geopolitical instability and the immediate financial impact of its internal digital and organizational restructuring efforts.
Revenue (FY26): ₹12,758 crNet Profit/Loss (FY26): -₹290 crGross Margin: 22%One-off costs: ₹236 crStandalone Debt: ₹314 cr
📅 Short termNegative sentiment is expected due to the reported loss and EBITDA turning negative, although the market may partially discount the one-off non-cash items.
📈 Long termThe structural shift towards AI-driven operations and cost optimization through Shared Service Centers (SSC) could improve margins if global trade volumes and yields stabilize.
⚠ Risk flags
- Geopolitical volatility impacting trade lanes
- Incremental freight capacity outpacing demand
- Execution risk of AI transformation
Key Highlights
Revenue declined 9% YoY to ₹12,758 cr in FY26 compared to ₹14,077 cr in FY25.
Reported a consolidated Net Loss of ₹290 cr against a profit of ₹43 cr in the previous year.
One-off exceptional and non-recurring costs totaled ₹236 cr, including ₹73 cr for PDD and ₹47 cr in notional forex losses.
Gross Margin improved by 200 bps to 22% despite lower volumes in LCL (8.5M Cbm) and FCL (643k TEU).
Standalone borrowings reduced by ₹36 cr to ₹314 cr as of March 31, 2026.
👀 What to Watch
Monitor the stabilization of yields and the realization of cost savings from the AI-led organizational transformation in upcoming quarters. Watch for recovery in global trade volumes, particularly in the high-value lanes mentioned in the management commentary.
NCLT Reserves Final Order for Demerger of Bio-Pharma and Spirits Units
India Glycols Limited (IGL) has reached the final stage of its corporate restructuring, with the NCLT Allahabad Bench reserving its final order on July 2, 2026. The scheme involves demerging the Nutraceuticals business into Ennature Bio pharma Limited and the Spirits business into IGL Spirits Limited. Regulatory reports from the RoC and Official Liquidator have been filed with no adverse observations. A minor tax demand of ₹27,890 was the only point of discussion, which the company has undertaken to settle if required post-sanction.
Confidence: HIGH
What changedThe legal proceedings for the demerger have concluded; the company is now awaiting the formal judicial verdict to execute the split of its business segments.
Why it mattersThis demerger is a significant value-unlocking exercise, separating the core chemical business from the high-growth Spirits and Bio-Pharma segments, potentially leading to a re-rating of the individual businesses.
Tax Demand: ₹27,890TTM Revenue: ₹8,443 CrMarket Cap: ₹6,830 CrResulting Companies: 2
📅 Short termPositive sentiment is expected as the company nears the completion of a long-awaited restructuring process.
📈 Long termStructural significance is high as it allows for independent management and capital allocation for the Spirits and Nutraceuticals divisions, which have different margin profiles than the base chemical business.
⚠ Risk flags
- Execution risk during the transition to three separate entities
- Market volatility during the listing process of the resulting companies
Key Highlights
NCLT reserved the matter for final pronouncement on July 2, 2026, following the second motion petition.
The restructuring involves spinning off two entities: Ennature Bio pharma Limited and IGL Spirits Limited.
RoC and Official Liquidator (Uttarakhand) reports contained no adverse observations regarding the scheme.
Income Tax Department raised a negligible demand of ₹27,890, which the company is prepared to address.
India Glycols (Demerged Company) will remain in existence post-approval to fulfill any outstanding liabilities.
👀 What to Watch
Investors should monitor the exchange for the final NCLT written order, which will lead to the announcement of the record date for share entitlement in the new entities.
Allcargo Global Limited (AGL) Lists on NSE and BSE Following 1:1 Demerger
Allcargo Global Limited (AGL) successfully commenced trading on the NSE and BSE on July 03, 2026, marking the completion of its demerger from Allcargo Logistics Limited. The restructuring provided shareholders of Allcargo Logistics with a 1:1 share entitlement, meaning one equity share of AGL was issued for every one share held in the parent company. AGL now operates as an independent entity focused on the international supply chain, housing ECU Worldwide, the world's largest LCL (Less than Container Load) consolidator. This listing concludes a four-year group transformation into four specialized listed entities.
Confidence: HIGH
What changedAllcargo Global Limited has transitioned from a division of Allcargo Logistics to an independently listed entity on the NSE and BSE.
Why it mattersThe demerger unlocks value by creating a pure-play international logistics company, allowing for dedicated capital allocation and management focus on global LCL and FCL markets.
Share Entitlement Ratio: 1:1Global Trade Coverage: over 90%Restructuring Duration: 4 yearsTotal Group Listed Entities: 4
📅 Short termThe stock will undergo a price discovery phase in the coming weeks as the market adjusts to the standalone valuation of the international supply chain business.
📈 Long termAGL is positioned to leverage its leadership in LCL consolidation; long-term success depends on global trade recovery and the scalability of its technology-driven logistics solutions.
⚠ Risk flags
- Exposure to global trade volume fluctuations
- Geopolitical risks affecting international shipping lanes
Key Highlights
1:1 share entitlement completed for shareholders of Allcargo Logistics Limited
AGL operates a global network covering markets that account for over 90% of global trade
Completion of a 4-year group restructuring resulting in 4 independent listed entities
Wholly owned subsidiary ECU Worldwide is recognized as the world's largest global LCL consolidator
Listing marks the transition of the international supply chain business into a standalone entity
👀 What to Watch
Investors should monitor AGL's standalone financial performance in upcoming quarterly results to evaluate the margin profile of the international supply chain business compared to the integrated entity. Watch for the adoption rate of their digital platform, ECU360, as a key driver for operational efficiency.
India Glycols Appoints Industry Veteran Manoj Kumar Rai as COO of IGL Spirits Subsidiary
India Glycols Limited has appointed Shri Manoj Kumar Rai as the Chief Operating Officer (COO) of its wholly-owned subsidiary, IGL Spirits Limited, effective July 2, 2026. Rai is a seasoned leader with 27 years of experience, most recently serving as the Chief Revenue Officer at Allied Blenders and Distillers Limited (ABDL). This strategic hire aligns with the company's goal to scale its potable spirits portfolio and premiumize its in-house brands like Zumba Lemoni and Soulmate Blu. Given the company's TTM revenue of ₹8,443 Cr and its focus on expanding distillery capacity (₹365 Cr capex), this leadership addition is significant for the spirits division's growth.
Confidence: HIGH
What changedIndia Glycols has hired a high-profile executive from a direct competitor (Allied Blenders) to lead its spirits subsidiary.
Why it mattersThe potable spirits segment is a focus for margin expansion; bringing in a veteran with deep P&L and revenue management experience is critical for competing with established players like Radico Khaitan and ABDL.
Experience of Appointee: 27 yearsTTM Revenue: ₹8,443 CrPlanned Distillery Capex: ₹365 CrEffective Date: July 2, 2026
📅 Short termSentimentally positive as it demonstrates the company's commitment to professionalizing and scaling its high-growth spirits business.
📈 Long termStructural positive; Rai's expertise in business transformation and commercial excellence could lead to better distribution and brand positioning for IGL's potable spirits.
⚠ Risk flags
- Execution risk in a highly regulated industry where state governments control pricing
Key Highlights
Appointment of Manoj Kumar Rai as COO of IGL Spirits Limited effective July 2, 2026
Rai brings over 27 years of experience from major firms including Allied Blenders and Distillers, Pernod Ricard, and Marico
Educational background includes a B.Tech from IIT Delhi and a PGDM from IIM Lucknow
The appointment targets the Potable Spirits segment, which is a key growth driver for the ₹6,660 Cr market cap company
Rai previously held the role of Chief Revenue Officer at a major industry peer (ABDL)
👀 What to Watch
Investors should monitor the pace of new brand launches and market share gains in the IMFL segment over the next 2-4 quarters to gauge the impact of this leadership change.
India Glycols FY26 PAT Jumps 26.8% to ₹293 Cr; Bio-Fuels EBIT Doubles
India Glycols Limited delivered a robust FY26 performance, with net revenue increasing 11.8% to ₹4,211 crores and PAT rising 26.8% to ₹293 crores. The Bio-Fuels segment was a standout performer, with EBIT doubling to ₹115 crores driven by India's 20% ethanol blending mandate. Operational efficiency improved significantly, as evidenced by EBITDA margins expanding 162 basis points to 15.5%. Furthermore, the company successfully deleveraged its balance sheet, bringing the debt-to-equity ratio down to 0.5x from 0.7x in FY23.
Key Highlights
FY26 EBITDA increased 24.5% YoY to ₹654 crores, with margins reaching 15.5%.
Bio-Fuels segment revenue grew 40.9% to ₹1,470 crores, while EBIT surged 103.3% to ₹115 crores.
Potable Spirits business maintained market leadership with 14.4% revenue growth to ₹1,331 crores.
Return on Capital Employed (ROCE) improved significantly to 11.9% in FY26 from 7.7% in FY23.
Chemicals segment EBIT rose 12.5% to ₹141 crores despite a 10.4% revenue decline, reflecting a shift to high-value products.
👀 What to Watch
The company's strategic shift toward premium spirits and specialty chemicals, coupled with a strengthening balance sheet, makes it a positive prospect. Investors should watch for continued execution in the Ennature Biopharma segment and global crude price trends affecting chemical competitiveness.
India Glycols Files ₹79.76 Crore Insurance Claim Recovery Against New India Assurance
India Glycols Limited has initiated legal action to recover an insurance claim of ₹79.76 Crore from The New India Assurance Co. Limited. The dispute relates to a 2020 claim for property damage, machinery breakdown, and business interruption at the company's Kashipur plant. After the insurer repeatedly repudiated the claim, India Glycols filed for Pre-Institution Mediation and Settlement before the Delhi High Court. The company believes it has a strong case on merits and is seeking the full claim amount plus interest.
Key Highlights
Initiated legal steps for recovery of ₹79.76 Crore towards material damage and loss of profit.
The claim pertains to an incident at the Kashipur Plant dating back to the year 2020.
Filed an application for Pre-Institution Mediation and Settlement before the Delhi High Court on May 21, 2026.
The claim was previously repudiated by The New India Assurance Co. Limited despite multiple representations.
Company is seeking the principal claim amount along with applicable interest.
👀 What to Watch
Investors should monitor the mediation and potential litigation outcomes, as a successful recovery of ₹79.76 Crore would represent a significant non-recurring gain for the company.
India Glycols NCLT Hearing for Demerger Postponed Due to Paucity of Time
India Glycols Limited (IGL) has reported a procedural delay in its ongoing corporate restructuring process. The NCLT Allahabad Bench was scheduled to hear the Second Motion Petition regarding the demerger of businesses into Ennature Biopharma Limited and IGL Spirits Limited on May 21, 2026. However, the hearing could not take place due to the court's time constraints, and a new date is currently awaited. This follows the initial admission of the petition on April 10, 2026.
Key Highlights
Hearing for the Scheme of Arrangement involving Ennature Biopharma and IGL Spirits was scheduled for May 21, 2026.
The NCLT Allahabad Bench postponed the matter due to paucity of time.
The petition relates to the Second Motion following the initial admission on April 10, 2026.
The next date of hearing is yet to be notified by the tribunal.
The restructuring aims to separate the biopharma and spirits businesses into distinct entities.
👀 What to Watch
Investors should view this as a routine procedural delay and continue to monitor for the next hearing date, as the demerger is a key value-unlocking event for the company.
India Glycols FY26 PAT Jumps 26.8% to ₹293 Cr; Announces Major Three-Way Demerger Plan
India Glycols (IGL) delivered a strong performance in FY26, with consolidated Net Revenue rising 11.8% to ₹4,211 Cr and PAT increasing 26.8% to ₹293 Cr. Growth was led by the Bio-Fuel segment (+40.9% YoY) and Potable Spirits (+14.4% YoY), while the company successfully reduced finance costs and doubled its cash flow from operations to ₹769 Cr. A significant value-unlocking demerger is underway to split the business into three separate listed entities focusing on Chemicals, Spirits/Bio-fuel, and Bio-pharma, with an NCLT hearing scheduled for May 21, 2026.
Key Highlights
FY26 Consolidated EBITDA grew 24.5% YoY to ₹654 Cr with margins expanding 162 bps to 15.5%.
Bio-Fuel segment revenue surged 40.9% to ₹1,470 Cr, driven by the national 20% ethanol blending program.
Potable Spirits segment reported ₹1,331 Cr revenue with a robust 21.4% EBIT margin, supported by premiumization.
Proposed demerger ratio: 1 share of Ennature Bio Pharma for every 3 IGL shares, and 1 share of IGL Spirits for every 1 IGL share.
Finance costs for Q4FY26 dropped to ₹26 Cr from ₹45 Cr YoY, reflecting significant debt reduction through internal accruals.
👀 What to Watch
The strong operational growth combined with a clear value-unlocking demerger strategy makes this a positive outlook for long-term investors. Shareholders should monitor the NCLT proceedings on May 21 for the final approval of the restructuring.
India Glycols FY26 PAT Jumps 56.5% to ₹282 Cr; Bio-Fuel Segment Revenue Surges 41%
India Glycols reported a strong financial performance for FY26, with standalone net profit rising 56.5% to ₹282.33 crore compared to ₹180.38 crore in FY25. Annual revenue from operations grew by 8.7% to reach ₹9,826.20 crore, driven largely by the Bio-Fuel and Potable Spirits segments. The Bio-Fuel segment showed exceptional growth, with revenue increasing from ₹1,043.55 crore to ₹1,469.93 crore. EBITDA margins improved significantly, with annual EBITDA rising 32.4% to ₹690.09 crore.
Key Highlights
Standalone Net Profit for FY26 increased by 56.5% YoY to ₹282.33 crore.
Revenue from operations for the full year grew 8.7% to ₹9,826.20 crore.
Bio-Fuel segment revenue surged by 40.8% YoY to ₹1,469.93 crore in FY26.
Q4 FY26 PAT saw a massive jump of 119% YoY, reaching ₹110.28 crore compared to ₹50.35 crore in Q4 FY25.
Annual Basic EPS improved significantly to ₹44.31 from ₹29.13 in the previous year.
👀 What to Watch
Investors should monitor the continued scaling of the high-growth Bio-Fuel segment and the company's ability to maintain these expanded margins. The strong bottom-line growth and improved EPS make it a positive outlook for long-term holders.
India Glycols FY26 Net Profit Surges 56% to ₹282 Cr; Q4 Profit Jumps 119% YoY
India Glycols reported a robust financial performance for FY26, with standalone annual net profit rising 56.5% to ₹282.33 crore. The fourth quarter was particularly strong, with net profit more than doubling to ₹110.28 crore compared to ₹50.35 crore in Q4FY25. Revenue growth was steady at 8.7% for the full year, reaching ₹9,826.20 crore. The Bio-Fuel segment emerged as a key growth driver, with its annual EBIT nearly doubling to ₹115.23 crore, reflecting improved operational efficiencies and market demand.
Key Highlights
Standalone Net Profit for FY26 increased by 56.5% YoY to ₹282.33 crore.
Q4 FY26 Net Profit surged 119% YoY to ₹110.28 crore from ₹50.35 crore.
Annual Revenue from Operations grew to ₹9,826.20 crore, up from ₹9,037.82 crore in FY25.
Bio-Fuel segment EBIT saw massive growth, reaching ₹115.23 crore in FY26 vs ₹56.68 crore in FY25.
Full-year Earnings Per Share (EPS) improved significantly to ₹44.31 from ₹29.13 in the previous year.
👀 What to Watch
The significant margin expansion in the Bio-Fuel segment and strong bottom-line growth make this a positive result for shareholders. Investors should maintain a positive outlook while monitoring the scalability of the Bio-based Specialities segment.
India Glycols Demerger Update: NCLT Admits Second Motion Petition for Biopharma and Spirits Units
India Glycols Limited (IGL) has announced that the NCLT Allahabad Bench admitted its second motion petition on April 9, 2026, regarding its proposed Scheme of Arrangement. The scheme involves the demerger of business divisions into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. The court has directed the company to issue statutory notices to authorities including SEBI and the Income Tax department, providing a 30-day window for representations. This procedural progress brings the company closer to completing its corporate restructuring aimed at unlocking value across its diverse business segments.
Key Highlights
NCLT Allahabad Bench admitted the Second Motion Petition for the demerger scheme on April 9, 2026.
The restructuring involves demerging assets into Ennature Biopharma Limited and IGL Spirits Limited.
Regulatory authorities and the public have been granted 30 days to file representations or objections.
The next NCLT hearing for further proceedings is scheduled for May 21, 2026.
The scheme remains subject to final regulatory approvals and the outcome of the upcoming hearing.
👀 What to Watch
Investors should view this as a positive step toward value unlocking through the separation of the biopharma and spirits businesses. Monitor the outcome of the May 21, 2026, NCLT hearing for final approval timelines.
India Glycols Unsecured Creditors Approve Demerger Scheme with 100% Majority
India Glycols Limited (IGL) has received unanimous approval from its unsecured creditors for a Scheme of Arrangement involving the demerger of businesses into Ennature Bio Pharma Limited and IGL Spirits Limited. The resolution was passed during an NCLT-convened meeting on March 24, 2026, with 100% of the polled votes in favor. This restructuring aims to separate the company's bio-pharma and spirits segments into distinct entities to potentially unlock shareholder value. The approval marks a significant milestone in the regulatory process required to finalize the corporate reorganization.
Key Highlights
Unsecured creditors approved the Scheme of Arrangement with 100% of the votes polled in favor.
The restructuring involves demerging business segments into Ennature Bio Pharma Limited and IGL Spirits Limited.
A total of 6,42,66,50,041 votes (by value) were polled during the meeting, all supporting the resolution.
The meeting was conducted via Video Conferencing as per the directions of the NCLT Allahabad Bench.
👀 What to Watch
Investors should monitor the subsequent NCLT hearings for final sanction of the scheme, which will lead to the creation of separate entities. This restructuring is likely to provide better focus on individual business segments and could lead to value unlocking for existing shareholders.
India Glycols Shareholders Approve Scheme of Arrangement with 100% Majority
Shareholders of India Glycols Limited have overwhelmingly approved a Scheme of Arrangement involving the restructuring of the company with Ennature Bio Pharma Limited and IGL Spirits Limited. In a court-convened meeting held on March 24, 2026, the special resolution received near-unanimous support, with 99.9999% of votes cast in favor. A total of 4.42 crore votes were polled, representing approximately 66.02% of the total shareholding. This restructuring is a strategic move likely aimed at separating business verticals to unlock shareholder value.
Key Highlights
Special resolution for Scheme of Arrangement passed with 4,42,48,625 votes in favor and only 1 vote against.
The arrangement involves India Glycols (Demerged Company), Ennature Bio Pharma, and IGL Spirits (Resulting Companies).
Total voting participation represented 66.02% of the company's total 6.70 crore outstanding shares.
The meeting was conducted via video conferencing following orders from the NCLT Allahabad Bench.
100% of the Promoter and Promoter Group votes (3.99 crore shares) were cast in favor of the resolution.
👀 What to Watch
Investors should view this as a positive step toward corporate restructuring and value unlocking; keep a watch for the final NCLT sanction and the record date for share allotments in the resulting companies.
India Glycols Declares ₹7.50 Interim Dividend; Sets Record Date for March 23, 2026
India Glycols Limited has declared an interim dividend of ₹7.50 per equity share (150% of face value) for the financial year 2025-26. The company has fixed March 23, 2026, as the record date to determine eligibility for the payout. Tax will be deducted at source (TDS) at a standard rate of 10% for resident individuals with a valid PAN, while a higher rate of 20% applies if the PAN is not linked with Aadhaar. Shareholders must submit relevant tax exemption documents by the record date to benefit from lower withholding rates.
Key Highlights
Interim dividend of ₹7.50 per share (150% of ₹5 face value) declared for FY 2025-26.
Record date for determining eligible shareholders is fixed as March 23, 2026.
Standard TDS of 10% for resident individuals with PAN; 20% for those without PAN or unlinked Aadhaar.
No TDS for resident individuals if the total dividend for the financial year does not exceed ₹10,000.
Non-resident shareholders may avail DTAA benefits by submitting TRC and Form 10F by the record date.
👀 What to Watch
Investors should ensure their PAN and Aadhaar are linked and submit tax-exemption forms like 15G/15H by March 23 to avoid higher TDS. To be eligible for the ₹7.50 dividend, shares must be held in the portfolio as of the record date.
India Glycols Declares Rs 7.5 Interim Dividend; Sets March 23 as Record Date
India Glycols Limited has announced an interim dividend of Rs 7.5 per equity share for the financial year 2025-26. This payout represents 150% of the face value of Rs 5 per share. The company has designated March 23, 2026, as the record date to identify eligible shareholders. The dividend is scheduled to be paid within 30 days from the declaration date of March 17, 2026.
Key Highlights
Interim dividend of Rs 7.5 per equity share declared for FY 2025-26
Dividend payout represents 150% of the face value of Rs 5 per share
Record date for shareholder eligibility fixed as March 23, 2026
Payment to be completed within 30 days from the declaration date
👀 What to Watch
Investors seeking to benefit from this dividend should ensure they hold the stock before the ex-dividend date. The 150% payout reflects a healthy cash distribution to shareholders.
India Glycols Declares Interim Dividend of Rs 7.5 Per Share (150%)
India Glycols Limited has announced an interim dividend of Rs. 7.5 per equity share for the financial year 2025-26. This payout corresponds to 150% of the face value of Rs. 5 per share. The Board has established March 23, 2026, as the record date for identifying eligible shareholders. The disbursement will occur within 30 days of the declaration date, providing a direct cash return to investors.
Key Highlights
Interim dividend of Rs. 7.5 per share declared for FY 2025-26.
Dividend payout represents 150% of the face value of Rs. 5.
Record date for shareholder eligibility set for March 23, 2026.
Payment to be completed within 30 days from March 17, 2026.
👀 What to Watch
Existing shareholders should hold their positions until the record date of March 23 to qualify for the payout. New investors interested in the dividend should ensure they purchase shares before the ex-dividend date.
India Glycols Receives Rs 38.88 Crore Interim Dividend from Clariant IGL JV
India Glycols Limited and its wholly-owned subsidiary have received a substantial interim dividend from their joint venture, Clariant IGL Specialty Chemical Private Limited. The JV declared a dividend of Rs 36,000 per share (3600%), resulting in a total gross receipt of Rs 38.88 crore for the group. Specifically, the parent company received Rs 36 crore while the subsidiary received Rs 2.88 crore. This significant cash inflow reflects the strong performance and liquidity of the joint venture entity.
Key Highlights
Total gross dividend inflow of Rs 38.88 crore from JV Clariant IGL Specialty Chemical Private Limited
JV declared an interim dividend of Rs 36,000 per equity share of face value Rs 10
India Glycols holds a 45.37% direct stake and 3.63% via a subsidiary in the JV
Net of TDS, the group received approximately Rs 34.99 crore in cash on March 17, 2026
👀 What to Watch
This is a positive development for liquidity and non-operating income; investors should monitor if these gains are passed on as dividends to IGL shareholders or used for debt reduction.
